Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Dr Reddy's Laboratories Ltd
Operating Income
Dr Reddy's Laboratories Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹67.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹58.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹122.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
4%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Operating Income
₹54.7B
|
CAGR 3-Years
23%
|
CAGR 5-Years
21%
|
CAGR 10-Years
15%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Operating Income
₹37.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
1%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹28.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
Dr Reddy's Laboratories Ltd
Glance View
In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.
See Also
What is Dr Reddy's Laboratories Ltd's Operating Income?
Operating Income
67.7B
INR
Based on the financial report for Dec 31, 2024, Dr Reddy's Laboratories Ltd's Operating Income amounts to 67.7B INR.
What is Dr Reddy's Laboratories Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
19%
Over the last year, the Operating Income growth was 8%. The average annual Operating Income growth rates for Dr Reddy's Laboratories Ltd have been 26% over the past three years , 19% over the past five years .
You don't have any saved screeners yet